counter on blogger
Tuesday, December 13, 2011
Is a Celiac cure in our future?
A number of articles popped up in my Google reader today about a vaccine for Celiac Disease. It looks like a major biotech company has secured $20 million to research Celiac Disease, create a development plan, and start clinical trials as soon as next year.

ImmusanT is "an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease." Their approach to treating Celiac Disease is based on immunotheraphy which will make gluten ingestion tolerant in a Celiac patient.

This all sounds really interesting to me, but I am still unsure how I feel about taking medication to eat food that I have avoided for 30 years. I definitely do not plan on participating in the clinical trial, but I am very interested to see how this research pans out over the next few years.


ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2®, companion diagnostic and monitoring tool for celiac disease. The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012.
Read the full press release here.

Biotech Secures $20 Million in Early Stage Financing
ImmusanT Inc. in Cambridge, Massachusetts has received $20 million in early stage financing to develop its therapy and diagnostic tools for celiac disease. The funds from venture capital firm Vatera Healthcare Partners LLC are expected to support further research and development of the company’s Nexvax2 therapeutics and diagnostics to a proof-of-concept demonstration.
Read more...


In other news:

Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, "Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance."
Read more...

Alvine's ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year
Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced today that the company's lead therapeutic product candidate for celiac disease, ALV003, has been selected by Windhover and its advisors as one of "The Top 10 Inflammatory/Autoimmune Projects to Watch in 2012." This is the second year that ALV003 has been named to the Top 10 list. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology and medical device industries. Alvine has been invited to present at Windhover's Therapeutic Area Partnerships Conference on December 1, 2011 in Boston, MA.
Read more...

Labels: , ,



1 Comments:

OpenID glutenismybitch said...

On a day like today, I'd totally sign up for this clinical trial. But hopefully I'll get over that impulse and remember that I can just stop eating gluten ;) Which sounds easy, yet is sometimes crazy-making.

Post a Comment

<< Home

© 2007, © 2013 Gluten-Free Fun
footer